Navigation Links
Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
Date:10/19/2010

ANAHEIM, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release financial results for the third quarter ended September 30, 2010 on Thursday, October 28, 2010 after the market close. The Company will host a conference call and webcast on Thursday, October 28, 2010 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the Company's third quarter results and current corporate developments.  The dial-in number for the conference call is 877-941-7133 for domestic participants and 480-629-9821 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days.  This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4378038#. To access the live webcast of the call, go to Questcor Pharmaceuticals' website at www.questcor.com. An archived webcast will also be available at www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company with products that help patients with serious, difficult-to-treat medical conditions.  Questcor markets H.P. Acthar® Gel (repository corticotropin injection), which is approved for the treatment of exacerbations associated with multiple sclerosis and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Questcor will market Acthar for the treatment of patients with infantile spasms, a rare form of refractory childhood epilepsy.  Acthar is also approved for 15 other indications. The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.  For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetech Announces Bankruptcy Court Approval of Merger With W. R. Grace Subsidiary
2. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
3. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
4. Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
5. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
6. Fate Therapeutics Announces Collaboration With BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology
7. Osteotech Announces Early Termination of HSR Waiting Period
8. ANGIOTECH PHARMACEUTICALS ANNOUNCES CONFERENCE CALL AND WEBCAST
9. Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants
10. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... applications consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding ... offers a broad range of contract analysis services for advanced applications. Services ...
(Date:10/7/2017)... Mass. , Oct. 6, 2017  The ... work of three scientists, Jacques Dubochet, Joachim ... breakthrough developments in cryo-electron microscopy (cryo-EM) ... technology within the structural biology community. The winners ... Scientists can now routinely produce highly resolved, three-dimensional ...
(Date:10/6/2017)... ... 2017 , ... On Tuesday, October 24th, ABC² (Accelerate Brain ... adaptive clinical trial for glioblastoma (GBM). The featured speaker will be Dr. Brian ... to the public, but registration is required. , WHAT: ABC² Brain Cancer ...
(Date:10/5/2017)... ... ... Understanding the microbiome, the millions of bacteria that live in our guts, ... Future, the newest exhibit on display at the University City Science Center’s Esther Klein ... lens of the gut microbiome. , Gut Love opens October 12, 2017, and ...
Breaking Biology Technology:
(Date:10/4/2017)... 2017  GCE Solutions, a global clinical research organization (CRO), announces ... solution on October 4, 2017. Shadow is designed to assist medical ... policy 0070 of the European Medicines Agency (EMA) in meeting the ... ... ...
(Date:8/15/2017)... HAMPTON, Va. , Aug. 15 2017   ivWatch LLC ... effectiveness of intravenous (IV) therapy, today announced receipt of its ISO ... (QMS) developed by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for ... "This ...
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
Breaking Biology News(10 mins):